Search CTL/CD8+ T-Cell Epitope Database

Found 28 matching records:

Displaying record number 52963

Download this epitope record as JSON.

HXB2 Location	Gag(254-262) p24(122-130) DNA(1549..1575)	Gag Epitope Map
Author Location	Gag(254-262)
Epitope	PPIPVGEIY	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B7 supertype)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52953

Download this epitope record as JSON.

HXB2 Location	Gag(259-267) p24(127-135) DNA(1564..1590)	Gag Epitope Map
Author Location	Gag(259-267)
Epitope	GEIYKRWII	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B8)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52945

Download this epitope record as JSON.

HXB2 Location	Gag(260-268) p24(128-136) DNA(1567..1593)	Gag Epitope Map
Author Location	Gag(260-268)
Epitope	EIYKRWIIL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52959

Download this epitope record as JSON.

HXB2 Location	Gag(261-270) p24(129-138) DNA(1570..1599)	Gag Epitope Map
Author Location	Gag(261-270)
Epitope	IYKRWIILGL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A24)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52955

Download this epitope record as JSON.

HXB2 Location	Gag(266-275) p24(134-143) DNA(1585..1614)	Gag Epitope Map
Author Location	Gag(266-275)
Epitope	IILGLNKIVR	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A11, A3)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52946

Download this epitope record as JSON.

HXB2 Location	Gag(267-274) p24(135-142) DNA(1588..1611)	Gag Epitope Map
Author Location	Gag(267-274)
Epitope	ILGLNKIV	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52956

Download this epitope record as JSON.

HXB2 Location	Gag(267-275) p24(135-143) DNA(1588..1614)	Gag Epitope Map
Author Location	Gag(267-275)
Epitope	ILGLNKIVR	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A11, A3)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52952

Download this epitope record as JSON.

HXB2 Location	Gag(267-277) p24(135-145) DNA(1588..1620)	Gag Epitope Map
Author Location	Gag(267-277)
Epitope	ILGLNKIVRMY	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(B7 supertype)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.
• A response to this peptide was induced in three patients after immunization with lipopeptides alone (no adjuvant) after the third and the fourth boost, and induced in two patients after immunization with lipopeptides and QS21 adjuvant after the third boost. Variant IyGLNKIVRMY was also recognized in two patients.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52954

Download this epitope record as JSON.

HXB2 Location	Gag(275-283) p24(143-151) DNA(1612..1638)	Gag Epitope Map
Author Location	Gag(275-283)
Epitope	RMYSPTSIL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52948

Download this epitope record as JSON.

HXB2 Location	Gag(276-283) p24(144-151) DNA(1615..1638)	Gag Epitope Map
Author Location	Gag(276-283)
Epitope	MYSPTSIL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A24)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52949

Download this epitope record as JSON.

HXB2 Location	Nef(68-76) DNA(8998..9024)	Nef Epitope Map
Author Location	Nef(68-76)
Epitope	FPVTPQVPL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B7 supertype)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52950

Download this epitope record as JSON.

HXB2 Location	Nef(71-79) DNA(9007..9033)	Nef Epitope Map
Author Location	Nef(71-79)
Epitope	TPQVPLRPM	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B7 supertype)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52960

Download this epitope record as JSON.

HXB2 Location	Nef(71-81) DNA(9007..9039)	Nef Epitope Map
Author Location	Nef(71-81)
Epitope	TPQVPLRPMTY	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(B7 supertype)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.
• A response was induced in one patient after immunization with lipopeptides alone (no adjuvant) after the third (W44) boost. A rPQVPLRPMTY variant was also recognized.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52957

Download this epitope record as JSON.

HXB2 Location	Nef(80-87) DNA(9034..9057)	Nef Epitope Map
Author Location	Nef(80-87)
Epitope	TYKAAVDL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A24)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52939

Download this epitope record as JSON.

HXB2 Location	Nef(82-91) DNA(9040..9069)	Nef Epitope Map
Author Location	Nef(82-91)
Epitope	KAALDLSHFL	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of 31 that the vaccinated volunteers responded to.
• A KAAvDLSHFL variant was cross-recognized after the last boost.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52940

Download this epitope record as JSON.

HXB2 Location	Nef(83-91) DNA(9043..9069)	Nef Epitope Map
Author Location	Nef(83-91)
Epitope	AAVDLSHFL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of 31 that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52941

Download this epitope record as JSON.

HXB2 Location	Nef(84-91) DNA(9046..9069)	Nef Epitope Map
Author Location	Nef(84-91)
Epitope	AVDLSHFL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of 31 that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52947

Download this epitope record as JSON.

HXB2 Location	Nef(84-92) DNA(9046..9072)	Nef Epitope Map
Author Location	Nef(84-92)
Epitope	AVDLSHFLK	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A11, A3)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52937

Download this epitope record as JSON.

HXB2 Location	Nef(121-128) DNA(9157..9180)	Nef Epitope Map
Author Location	Nef(121-128)
Epitope	FPDWQNYT	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A1)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of 31 that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52961

Download this epitope record as JSON.

HXB2 Location	Nef(128-135) DNA(9178..9201)	Nef Epitope Map
Author Location	Nef(128-135)
Epitope	TPGPGVRY	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B7 supertype)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52962

Download this epitope record as JSON.

HXB2 Location	Nef(128-137) DNA(9178..9207)	Nef Epitope Map
Author Location	Nef(128-137)
Epitope	TPGPGVRYPL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B7 supertype)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52958

Download this epitope record as JSON.

HXB2 Location	Nef(134-143) DNA(9196..9225)	Nef Epitope Map
Author Location	Nef(134-143)
Epitope	RYPLTFGWCY	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A24)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52951

Download this epitope record as JSON.

HXB2 Location	Nef(135-143) DNA(9199..9225)	Nef Epitope Map
Author Location	Nef(135-143)
Epitope	YPLTFGWCY	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B7 supertype)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the most frequently recognized of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52942

Download this epitope record as JSON.

HXB2 Location	Nef(136-145) DNA(9202..9231)	Nef Epitope Map
Author Location	Nef(136-145)
Epitope	PLTFGWCYKL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This was one of the most highly recognized of the 31 peptides that were shown to elicit a response.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52943

Download this epitope record as JSON.

HXB2 Location	Nef(137-145) DNA(9205..9231)	Nef Epitope Map
Author Location	Nef(137-145)
Epitope	LTFGWCYKL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This was one of the most highly recognized of the 31 peptides that were shown to elicit a response.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52964

Download this epitope record as JSON.

HXB2 Location	Nef(182-189) DNA(9340..9363)	Nef Epitope Map
Author Location	Nef(182-189)
Epitope	EWRFDSRL	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(B8)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of the 31 epitopes that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52944

Download this epitope record as JSON.

HXB2 Location	Nef(190-198) DNA(9364..9390)	Nef Epitope Map
Author Location	Nef(190-198)
Epitope	ALHHVAREL	Epitope Alignment
		Show epitope variants
Subtype	B
Species (MHC/HLA)	human(A2)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of 31 that the vaccinated volunteers responded to.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---

Displaying record number 52938

Download this epitope record as JSON.

HXB2 Location	Nef(195-202) DNA(9379..9402)	Nef Epitope Map
Author Location	Nef(195-202)
Epitope	ARELHPEY	Epitope Alignment
Subtype	B
Species (MHC/HLA)	human(A1)
Immunogen	vaccine
Experimental methods	CD8 T-cell Elispot - IFNγ, Chromium-release assay, Proliferation
Keywords	vaccine-induced immune responses, variant cross-reactivity

Vaccine Details

Vaccine type	lipopeptide
Vaccine strain	B clade LAI
Vaccine component	Env, Gag, Nef
Adjuvant	QS21

Notes

• After injection of an anti-HIV-1 lipopeptide vaccine and the booster injections, a response was observed in >85% of 28 volunteers, and a long-term immune response was observed in >50% of the volunteers. A positive effect of QS21 adjuvant was found for B-and CD4+T-cell responses. A higher number of CD8+ T-cell epitopes was induced after a fourth boost injection. This epitope was one of 31 that were recognized in the vaccinees.

References

Gahery-Segard2003 Hanne Gahéry-Ségard, Gilles Pialoux, Suzanne Figueiredo, Céline Igéa, Mathieu Surenaud, Jessintha Gaston, Helene Gras-Masse, Jean-Paul Lévy, and Jean-Gérard Guillet. Long-Term Specific Immune Responses Induced in Humans by a Human Immunodeficiency Virus Type 1 Lipopeptide Vaccine: Characterization of CD8+-T-Cell Epitopes Recognized. J. Virol., 77(20):11220-11231, Oct 2003. PubMed ID: 14512570. Show all entries for this paper.

---